Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$47.41M$47.41M−0.8% vs Q1 2020 Net Income-$53.87M-$53.87MN/M vs Q1 2020 EPS Diluted-$0.96-$0.96N/M vs Q1 2020 Operating Income-$47,549,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$30,969,000N/M Margins · derivedOperating margin-100.3%−68.8 pt vs Q1 2020
Net margin-113.6%−115.3 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end